Neurometa Therapeutics ApS: Financial statements 2024
CVR: 44557703
Source: annual report 2024, Danish Business Authority
02/01/2024 – 31/12/2024
Neurometa Therapeutics ApS (CVR 44557703) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -32,077 and a net result of DKK -285,786. Equity in the 2024 report amounted to DKK 60,877. The solvency ratio was 79.2%.
- Gross Profit
- DKK -32,077
- Profit/Loss
- DKK -285,786
- Equity
- DKK 60,877
- Total Assets
- DKK 76,907
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
As of January 2, 2024, Preben Bruun-Nyzell is registered as director of Neurometa Therapeutics ApS.
As of January 2, 2024, Josephus Dirk Vestergaard Nieland is registered as director of Neurometa Therapeutics ApS.
As of January 2, 2024, Steinunn Sara Helgudóttir is registered as director of Neurometa Therapeutics ApS.
As of January 2, 2024, Anne Skøttrup Mørkholt is registered as director of Neurometa Therapeutics ApS.
Neurometa Therapeutics ApS was founded on January 2, 2024.
About Neurometa Therapeutics ApS
Neurometa Therapeutics ApS is a Danish company of the type Anpartsselskab based in Aalborg Øst, founded in 2024. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Geysir Therapeutics ApS. The management consists of Josephus Dirk Vestergaard Nieland, Preben Bruun-Nyzell and Steinunn Sara Helgudóttir. The company is owned by Neurometa Therapeutics AB. The company has 2 employees (2026). In 2025, the company reported a gross profit of DKK -17,476 and a net result of DKK -18,563 compared with DKK -285,786 the year before. Equity in the 2025 report amounted to DKK -264,349.